Hoxton Planning & Management LLC Acquires 4,092 Shares of Haleon plc (NYSE:HLN)

Hoxton Planning & Management LLC increased its position in shares of Haleon plc (NYSE:HLNFree Report) by 39.5% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 14,450 shares of the company’s stock after buying an additional 4,092 shares during the period. Hoxton Planning & Management LLC’s holdings in Haleon were worth $123,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Clearbridge Investments LLC increased its position in Haleon by 2.4% during the fourth quarter. Clearbridge Investments LLC now owns 26,581,902 shares of the company’s stock worth $218,769,000 after purchasing an additional 612,400 shares during the last quarter. Wellington Management Group LLP raised its stake in shares of Haleon by 164.6% in the 4th quarter. Wellington Management Group LLP now owns 13,542,346 shares of the company’s stock valued at $111,454,000 after acquiring an additional 8,423,475 shares during the period. Douglas Lane & Associates LLC raised its stake in shares of Haleon by 2.1% in the 1st quarter. Douglas Lane & Associates LLC now owns 8,401,876 shares of the company’s stock valued at $71,332,000 after acquiring an additional 175,082 shares during the period. Goldman Sachs Group Inc. raised its stake in shares of Haleon by 19.1% in the 4th quarter. Goldman Sachs Group Inc. now owns 4,813,997 shares of the company’s stock valued at $39,619,000 after acquiring an additional 772,829 shares during the period. Finally, Northern Trust Corp increased its stake in Haleon by 3.0% during the 3rd quarter. Northern Trust Corp now owns 3,455,293 shares of the company’s stock worth $28,783,000 after buying an additional 101,562 shares during the period. 6.67% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have commented on HLN. Berenberg Bank began coverage on shares of Haleon in a report on Wednesday, June 5th. They set a “buy” rating for the company. Argus reiterated a “buy” rating on shares of Haleon in a report on Tuesday, March 26th. Finally, HSBC initiated coverage on shares of Haleon in a report on Wednesday, April 17th. They issued a “buy” rating for the company. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy”.

Get Our Latest Stock Analysis on Haleon

Haleon Trading Down 0.8 %

NYSE HLN traded down $0.07 during mid-day trading on Tuesday, hitting $8.57. The company’s stock had a trading volume of 2,214,941 shares, compared to its average volume of 5,466,607. The firm has a market capitalization of $39.13 billion, a P/E ratio of 28.80, a price-to-earnings-growth ratio of 2.27 and a beta of 0.26. The stock’s fifty day simple moving average is $8.39 and its two-hundred day simple moving average is $8.34. Haleon plc has a 52-week low of $7.70 and a 52-week high of $8.96. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.04 and a quick ratio of 0.73.

Haleon (NYSE:HLNGet Free Report) last posted its quarterly earnings data on Wednesday, May 1st. The company reported $0.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.01. The firm had revenue of $3.70 billion for the quarter, compared to the consensus estimate of $3.71 billion. Haleon had a return on equity of 13.17% and a net margin of 9.68%. Research analysts expect that Haleon plc will post 0.46 EPS for the current year.

Haleon Profile

(Free Report)

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.

See Also

Want to see what other hedge funds are holding HLN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haleon plc (NYSE:HLNFree Report).

Institutional Ownership by Quarter for Haleon (NYSE:HLN)

Receive News & Ratings for Haleon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haleon and related companies with MarketBeat.com's FREE daily email newsletter.